Darla Ann Dash

* ******* ***

Colchester, CT ****5

adw27x@r.postjobfree.com 860-***-****

CAREER SUMMERY

Expert in vivo pharmacologist and team player that successfully drives projects forward, whose background covers animal husbandry, developing protocols and ovel in vivo methods and techniques, encompassing a diverse background of animal species. Responsible for training colleagues with IACCUC approved in vivo methods. Able to establish relationships and communicate effectively at all levels. Seeking a position where I can continue to contribute both individually and as team member to support successful drug discovery.

KEY ACCLOMPLISHMENTS

Coordinated and performed critical in vivo studies that contributed to the identification of multiple clinical candidates.

Harmonized communications, resourcing and sample handling across partner lines including Chemistry, PDM, Safety Sciences, Laboratory Animal Resources, Animal Care, Compound Management, and Procurement resulting in increased efficiency in data generation and decision making.

Identified study protocol problems associated with dosing and implemented novel cage card system that increased data accuracy and integrity, adopted as standard policy within department.

Negotiated pricing, procedures, and reagents with vendors to achieve lowest prices.

Maintained Animal User Protocol, records SOPs,

IACCUC certified for mouse, rat, gerbil, and hamster species.

As the most senior in vivo scientist, I was responsible for oversight of proper protocols, including making sure that the new and less experienced colleagues were performing at proper IACUC standards. I set up a training program for these scientists and was acknowledged in a recent OSHA site wide newsletter.

TECHNICAL EXPERTISE

Multiple techniques for handling mouse, rat, gerbil, hamster, guinea pig, rabbit, dog, pig, and monkeys.

Bleeding techniques including orbital, vena cava, femoral, abdominal aorta, cardiac terminal, jugular, ear vein, and tail vein.

Delivery systems including subcutaneous, intramuscular, intravenous, intraperitoneal, and orbital injection.

Various dosing methods including oral gavage, intraperitoneal, subcutaneous, intramuscular, and vena cava dosing.

Animal necropsy and tissue removal including liver, lung, quadricep muscle, fat (abdominal and epididymal), kidney, heart and skin.

Ensured compliance with IACCUC, FDA, AALAC and USDA guidelines for animal husbandry

CAREER HISTORY

Pfizer Global Research and Development, MRU, Cambridge, Massachusetts 2012-2023

Associate Scientist, Cardiovascular Diabetes

Principle investigator for in vivo studies, responsible for purchasing supplies, defining dosing regimens, collecting samples (tissue, plasma, serum, urine), monitoring metabolic parameters (OGTT, IPTT), studies That are performed in reverse light dark cycle room, Body Composition analyzer evaluation of rats and mice, tumor measurement and excision in nude mice.

Responsible for training new colleagues with IACUC approved methods

Pfizer Global Research and Development, Groton Laboratories, Connecticut 2007-2012

Assistant Scientist, Cardiovascular Diabetes

Principle investigator for in vivo studies, responsible for purchasing supplies, defining dosing regimens, collecting samples (tissue, plasma, serum, urine), monitoring metabolic parameters (OGTT, IPTT), Metabolic cage studies in mice and rats, radioactive vena cava injections in rats.

Colleagues adopted the cage card system I developed in Ann Arbor, MI.

Responsible for training new colleagues with IACUC approved methods.

Pfizer Global Research and Development/Warner-Lambert, Ann Arbor Laboratories, MI 1993-2007

Coordinator of animal studies for compound evaluation. Responsibilities also include organization of in vivo teams for model development and resourcing studies which involved training, scheduling, ordering, animal welfare, and safety.

Designed critical laboratory equipment that increased efficiency of animal studies that met IACUC requirements.

Designed cage card system adopted as standard protocol for departmental in vivo team.

PUBLICATIONS

1.Auerbach BJ, Dash D, Bousley D, Essenburg A, Davila-Delgado E, Bocan T, Homan R, Kraus BR. The ACAT inhibitor, avasimibe, reduces aortic cholesterol content in apoE knockout mice, independent of its plasma hypocholesterolemic effects. Atherosclerosis. 151(1):65-, 2000.

2.Auerbach BJ, Dash D, Bousley D, Davila-Delgado E, Essenburg A, Krause BR. Treatment of endogenous hypercholesterolemic rabbits with CI-1027, a novel lipid regulator, results in significantly increased HDL-C and decreased LDL-C. Atherosclerosis. 151(1):65-, 2000.

3.Auerbach BJ, Bousley R, Dash D, Bisgaier CL, Essenburg AD, McGuire E, Manca D, Radulovic L, Gibson D, Krause BR, Keiser JA. CI-1027 reduces elevated Lp(a) concentrations in cynomolgus monkeys and Lp(a) transgenic mice. Atherosclerosis. 144, Suppl. 1:96-, 1999.

Contact this candidate